Stifel analyst Andrew Partheniou lowered the firm’s price target on Trulieve Cannabis to C$8 from C$20 and keeps a Buy rating on the shares. The firm is reducing its broader core MSO market estimates by 9% in 2024 and modifying its valuation methodology for U.S. cannabis producers for “low growth.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TCNNF:
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Trulieve Cannabis appoints Ryan Blust as interim CFO
- Rising High: Exclusive talk with biotech company Enveric Biosciences
- CytoSorbents appoints D’Amico as Chief Financial Officer
- Rising High: Exclusive talk with mental healthcare company Numinus